ストックスクリーナーアプリを入手
165.60
2.25%
3.65
前日終値:
$161.95
開ける：
$162.89
24時間の取引高:
839.52K
Relative Volume:
0.62
時価総額：
$22.73B
収益：
$1.96B
当期純損益:
$-253.24M
株価収益率:
-86.70
EPS:
-1.91
ネットキャッシュフロー:
$94.06M
1週間 パフォーマンス:
+1.58%
1か月 パフォーマンス:
+18.35%
6か月 パフォーマンス:
+2.03%
1年 パフォーマンス:
+35.06%
1日の値動き範囲:
$161.86
$166.31
1週間の範囲:
$156.71
$166.31
52週間の値動き範囲:
$110.57
$183.00
Natera Inc Stock (NTRA) Company Profile
NTRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
165.60 | 22.12B | 1.96B | -253.24M | 94.06M | -1.91 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-08 | 再開されました | Craig Hallum | Buy |
| 2024-02-20 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-11-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 開始されました | Bernstein | Mkt Perform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-05-05 | 開始されました | UBS | Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-04-25 | 開始されました | Stephens | Overweight |
| 2022-03-08 | 開始されました | Goldman | Buy |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-05-25 | 開始されました | Wells Fargo | Overweight |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-10-08 | 開始されました | BTIG Research | Buy |
| 2020-09-28 | 開始されました | Morgan Stanley | Overweight |
| 2020-09-17 | 開始されました | SVB Leerink | Outperform |
| 2020-06-10 | 再開されました | Piper Sandler | Overweight |
| 2020-05-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 開始されました | JP Morgan | Neutral |
| 2018-07-05 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-08-07 | 繰り返されました | Morgan Stanley | Overweight |
| 2016-11-10 | 繰り返されました | The Benchmark Company | Buy |
| 2016-05-23 | 繰り返されました | The Benchmark Company | Buy |
| 2016-05-11 | 繰り返されました | The Benchmark Company | Buy |
| 2016-04-19 | 開始されました | The Benchmark Company | Buy |
| 2015-09-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2015-08-14 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 開始されました | Robert W. Baird | Outperform |
| 2015-07-27 | 開始されました | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 開始されました | Piper Jaffray | Overweight |
| 2015-07-27 | 開始されました | Wedbush | Neutral |
すべてを表示
Natera Inc (NTRA) 最新ニュース
Natera Bounces 0.32% on 37% Volume Surge as Stock Ranks 471st Amid Mixed Institutional Moves and Analyst Outlooks - AInvest
Non-Invasive Prenatal Screening Market 2025-2032: Advanced - openPR.com
CareDx gets $96M jury verdict overturned in Natera patent dispute - MSN
Natera says IMvigor011 bladder cancer trial achieves positive results - MSN
Natera (NTRA) Reports Positive Phase III Trial Results in Muscle-Invasive Bladder Cancer - simplywall.st
Natera, Inc.IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera Strongly Predicting Adjuvant Immunotherapy Benefit - MarketScreener
Natera stock rises on positive bladder cancer trial results, UBS reiterates Buy - Investing.com
Natera pursues ctDNA assay approval after Phase III victory - Clinical Trials Arena
Natera’s bladder cancer test shows survival benefits in phase III trial By Investing.com - Investing.com South Africa
Natera’s bladder cancer test shows survival benefits in phase III trial - Investing.com Canada
98% 18-Month Survival Rate: Natera's Breakthrough Bladder Cancer Test Proves Critical for Immunotherapy Success - Stock Titan
Natera (NTRA) Is Up 7.3% After Raising 2025 Revenue Guidance and Launching Fetal Focus Test Has The Bull Case Changed? - ca.finance.yahoo.com
Natera (NTRA) Is Up 7.3% After Launching Fetal Focus and Raising 2025 Revenue Guidance - simplywall.st
What is Natera Inc. s revenue forecastQuarterly Portfolio Summary & Weekly Top Stock Performers List - thegnnews.com
Natera president sells $136k in stock By Investing.com - Investing.com Nigeria
Natera: President Fesko sells $105k in shares By Investing.com - Investing.com Nigeria
Natera president sells $136k in stock - Investing.com India
Natera: President Fesko sells $105k in shares - Investing.com
Natera Surges 2.89% on $240M Volume as Institutional Buyers Pile In Stock Ranks 423rd in Market Activity Amid Analyst Upgrades - AInvest
LabCorp Fails to Block Natera Patent-Invalidity Claims Pre-Trial - Bloomberg Law News
Live Scanner Shows Breakout on Natera Inc.Big Profit Small Risk Alerts - beatles.ru
Can Natera Inc. Regain Momentum After Breakdown2025 Winners & Losers & Advanced Technical Analysis Signals - beatles.ru
Natera’s Strong Growth Potential and Market Leadership Justify Buy Rating - TipRanks
Natera Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 EndofMonth & Fast Entry Momentum Trade Alerts - sundaytimes.kr
Non-invasive Prenatal Testing Market Set to Witness Massive - openPR.com
Natera price target raised to $195 from $185 at Morgan Stanley - MSN
5 Revealing Analyst Questions From Natera’s Q2 Earnings Call - Yahoo Finance
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics - MSN
Natera (NTRA) Q2 Results: 32% Revenue Growth, Strong Buy RatingNews and Statistics - IndexBox
Natera Q2 Earnings Call Highlights Strong Growth, Raises Revenue Guidance and Announces New Product Launches and Innovations - AInvest
1 ‘Strong Buy’ Stock Analysts Think Will Soar 62% - Yahoo Finance
Natera (NTRA) Is Up 14.1% After Raising Revenue Guidance and Launching New Prenatal Test – Has the Bull Case Changed? - simplywall.st
Natera Insider Sold Shares Worth $958,059, According to a Recent SEC Filing - MarketScreener
Natera director Sheena Jonathan sells $958k in NTRA stock - Investing.com
Natera director Sheena Jonathan sells $958k in NTRA stock By Investing.com - Investing.com Australia
Natera Inc. Reports Strong Growth and Strategic Advances - TipRanks
Natera at Canaccord Conference: Growth and Innovation in Focus - Investing.com
Natera at Canaccord Conference: Growth and Innovation in Focus By Investing.com - Investing.com Australia
Natera Surges 1.76% on $290M Volume, Climbs to 356th in Market Activity - AInvest
How clinicogenomic data are reshaping kidney disease trials and drug discovery - Nature
New noninvasive prenatal test can screen for CF, other genetic diseases - Cystic Fibrosis News Today
Leerink Partners Maintains Natera(NTRA.US) With Buy Rating, Announces Target Price $235 - 富途牛牛
NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures - TradingView
Natera Surges 3.35% as Daily Volume Slumps 49.12% to 310M Dollar Ranking 335th in Market Activity - AInvest
Natera Stock Jumps 13.69% In 3 Days As Technicals Signal Bullish Reversal - AInvest
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (CTKB), Natera (NTRA) and Warby Parker (WRBY) - The Globe and Mail
Natera: Piper Sandler Raises PT to $220 from $210, Maintains Overweight - AInvest
Natera And 2 Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates - MSN
Mixed Analyst Opinions on Healthcare Stocks Cytek Biosciences, Natera, and Warby Parker - AInvest
Natera introduces prenatal test for detecting inherited conditions - MSN
Natera Inc (NTRA) 財務データ
収益
当期純利益
現金流量
EPS
Natera Inc (NTRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER |
Aug 14 '25 |
Sale |
155.46 |
678 |
105,401 |
152,747 |
| Sheena Jonathan | CO-FOUNDER |
Aug 08 '25 |
Sale |
161.90 |
3,070 |
497,047 |
242,252 |
| Sheena Jonathan | CO-FOUNDER |
Aug 11 '25 |
Sale |
153.67 |
3,000 |
461,012 |
34,282 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Aug 01 '25 |
Sale |
132.88 |
5,807 |
771,656 |
163,593 |
| Marcus Gail Boxer | Director |
Aug 01 '25 |
Sale |
133.17 |
2,496 |
332,395 |
5,763 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Aug 01 '25 |
Sale |
132.89 |
3,000 |
398,657 |
123,059 |
0.59%
1.90%
大文字化:
|
ボリューム (24 時間):